Business
Philippe P. Calais to Join Marina Biotech's Board of Directors
Philippe P. Calais to Join Marina Biotech's Board of Directors.
About this update from Adhera Therapeutics Inc.
[{"type":"text","content":"\n \n \n Philippe P. Calais to Join Marina Biotech's Board of Directors\n \n \nPhilippe P. Calais to Join Marina Biotech's Board of Directors\n \n CITY OF INDUSTRY, CA--(Marketwired - Dec 14, 2016) - Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for cancer and rare diseases, today announced that Dr. Philippe P. Calais was elected to the Marina Biotech board of directors, which he will join effective January 1, 2017. Dr. Calais currently serves as Chief Executive Officer of Isarna Therapeutics. \n \"We are delighted to welcome Philippe to the Marina board of directors,\" said Joseph Ramelli, CEO of Marina Biotech. \"His breadth of knowledge, experience, and connections in the biotech industry are truly impressive and we look forward to his future contributions to the company. His experience with development and commercialization of antisense therapeutics will prove invaluable as we continue to unlock the potential of Marina's oligo therapeutic assets.\"\n \"I am delighted to join the board of Marina,\" said Dr. Calais. \"Working closely with Vuong for the last 2.5 years, I came to recognize the depth of his scientific leadership as well as his unique accomplishments to strengthen his company network, Marina being the most recent example of his innovative vision. I look forward to bringing my experience and expertise to serve Marina's board and management in order to take the new company to new heights!''\n Dr. Calais has over 28 years of biopharmaceutical and pharmaceutical industry experience in North America and Europe. Prior to becoming CEO of Isarna Therapeutics, he managed several biopharmaceutical companies in Canada and in Europe and headed a large technology transfer organization, focusing on corporate strategic positioning, company deployment and sales optimization strategies. His management expertise, combined with extensive experience with large pharma companies, such as ICI Pharmaceuticals and Roche, covers the full scope of the drug chain -- from discovery to clinical development, commercialization as well as partnership and franchise strategic marketing for several therapeutic areas. He has successfully raised significant financing internationally for private and publicly traded biotechs. A French citizen residing in German...